Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer Society's annual report on cancer incidence and mortality. But there is a wide ...

Nintendo has finally revealed its new console, Nintendo Switch 2, and we’ve published the first images in a gallery below. In a Nintendo Switch 2 reveal video published on Thursday, the platform ...

The fires continue to burn, and the full extent of the damage is still unknown. These latest photos show what's left of places thousands of people call home: What caused the massive blaze in ...

The filmmaker possessed a singular vision — and a knack for finding collaborators who could convey it. The filmmaker possessed a singular vision — and a knack for finding collaborators who ...

Nintendo has finally lifted the lid on Switch 2 and... well, it looks an awful lot like the Switch. But there are subtle differences, a few obvious new additions, and still some intriguing ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...